Every 10-Q that INHIBITOR THERAPTICS INC (INTI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INTI filings page.
Inhibitor Therapeutics, Inc. reported no revenue and a net loss of $1.3 million for the six months ended June 30, 2026, similar to 2025. Operating cash outflow was $1.9 million, leaving cash of $515,758 and total assets of $637,190 versus liabilities of $3.2 million, including $3.0 million of non‑current deferred revenue. The company states that these conditions raise substantial doubt about its ability to continue as a going concern.
The company depends on advancing itraconazole for basal cell carcinoma nevus syndrome. During 2026 it shifted its proposed primary efficacy endpoint to the rate and response of surgically eligible basal cell carcinomas and requested FDA feedback via a Type C meeting, with written responses expected by the end of September 2026. A pilot bioavailability study showed the Avior-developed 75 mg itraconazole capsule had pharmacokinetics generally comparable to TOLSURA, and a provisional U.S. patent application was filed for the amorphous nano/microparticle formulation. Itraconazole holds FDA Orphan Drug Designation for BCCNS. A February 2026 securities purchase agreement for $3.0 million remains unfunded; the company has obtained a default judgment and is pursuing collection, but has not recorded any receivable.
Inhibitor Therapeutics, Inc. reported a Q1 2026 net loss of $0.7 million with no revenue, reflecting its development-stage focus. Research and development expenses were $0.3 million and general and administrative expenses were $0.4 million.
Cash and cash equivalents declined to $1.29 million as of March 31, 2026, with negative operating cash flow of $1.08 million. Total assets were $1.43 million versus total liabilities of $3.41 million, resulting in a stockholders’ deficit of $2.0 million.
The company disclosed substantial doubt about its ability to continue as a going concern, citing recurring losses, limited cash and projected liquidity shortfalls. A planned $3.0 million registered direct financing for common stock and warrants has not funded, and the company has initiated litigation against the investor over the securities purchase agreement, adding uncertainty around future liquidity.
Inhibitor Therapeutics (INTI) reported Q3 2025 results marked by ongoing development work and no product revenue. The company posted a net loss of $712,184 for the quarter and $2,004,972 for the nine months. Operating expenses were steady, with R&D $377,789 and G&A $363,426 in Q3. Interest income was $29,031 in Q3.
Cash and cash equivalents were $2,976,658 as of September 30, 2025 (from $5,606,863 at year-end), reflecting net cash used in operations of $2,630,205 year-to-date. The balance sheet shows $3,000,000 in deferred royalty advances tied to the BCCNS program. The company advanced regulatory preparations around itraconazole for BCCNS, engaged Avior for a finalized formulation and a PK crossover study, and applied to FDA’s RDEA pilot. Subsequent events include a 2025 Equity Incentive Plan for up to 20,000,000 shares subject to shareholder approval and a performance-based consulting agreement with Frameshift featuring warrant eligibility upon defined milestones. 172,573,545 shares were outstanding as of November 13, 2025.